Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholder's Equity (Tables)

Stockholder's Equity (Tables) - Service-Based Vesting Condition Options [Member]

3 Months Ended

Feb. 28, 2019

Stock option activity for the three months ended February 28, 2019, was as follows:


				Weighted		Weighted Average
				Average		Remaining		Aggregate
	Options			Exercise Price		Contractual Life (Years)		Intrinsic Value
Outstanding at November 30, 2018		1,001,365		$	2.77		3.97	$	4,580,967
Granted		—			—				—
Exercised		(2,500	)		2.28				14,175
Expired/forfeited		(5,000	)		2.23				21,625

Outstanding at February 28, 2019		993,865		$	2.78		3.75	$	3,827,501

Exercisable at February 28, 2019		970,821		$	2.68		3.73	$	3,813,041

Significant Option Groups Exercisable Option and its Price and Contractual Life

Significant option groups exercisable at February 28, 2019 and related price and contractual life information are as follows:


	Outstanding						Exercisable
			Weighted Average
			Remaining		Weighted				Weighted
Range of Exercise Prices	Outstanding		Contractual Life (Years)		Average Exercise Price		Outstanding		Average Exercise Price
$1.01 to $2.00		422,500		2.69	$	1.73		422,500	$	1.73
$2.01 to $3.00		267,500		2.13	$	2.72		267,500	$	2.72
$3.01 to $4.00		227,229		6.92	$	3.18		223,062	$	3.18
$6.01 to $7.00		25,000		8.09	$	6.95		23,334	$	6.98
$7.01 to $8.00		51,636		4.83	$	7.85		34,425	$	7.85

		993,865		3.75	$	2.78		970,821	$	2.68

Summary of Non-Vested Options

A summary of the status of the Company’s non-vested options as of February 28, 2019, and changes during the three months ended February 28, 2019, is presented below:


				Weighted Average
				Grant-Date
	Options			Fair Value
Non-vested at November 30, 2018		40,254		$	3.06
Granted		—			—
Vested		(17,210	)		3.23
Forfeited		—			—

Non-vested at February 28, 2019		23,044		$	2.94